Cat. No. Name Size Price Add Cart
KI0576PF-25459205 mg$526
PF-254592010 mg$722
PF-254592050 mg$1896
PF-2545920200 mg$5220

Chemical Characteristic

Product NamePF-2545920
SynonymsMP-10
CAS No.1292799-56-4
Molecular Weight 392.45
FormulaC25H20N4O
Chemical Name2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinoline
Smilesn1c(ccc2ccccc12)COc1ccc(cc1)c1nn(cc1c1ccncc1)C
Chemical Structure

Biological activities

PF-2545920 is a specific phosphodiesterase-10A (PDE10A) inhibitor.[1] PF-2545920 inhibits PDE10A with an IC50 of 0.18 nM. [2] PF-2545920 inhibits human phosphodiesterases (hPDE10, hPDE2A and hPDE4A) with IC50 of 1.26 nM, 3.6 and 1.7 μM, respectively. [3] Pre-dosing of rats with PF-2545920 (1 mg/kg) reduce tracer uptake in the striatum by 14% relative to the tracer uptake in the cerebellum. [1] PF-2545920 causes some increases in GluR1 phosphorylation levels of 3-, 5.4-, and 4.1-fold with 0.3, 3, and 5 mg/kg doses, respectively. PF-2545920 (3 mg/kg) increases both enkephalin and substance-P mRNA levels. PF-2545920 (0.1-30 mg/kg i.p.) produces a decrease in apomorphine-induced climbing in mice with an ID50 of 0.375 mg/kg and decreases apomorphine-induced stereotypy with an ID50 of 25.069 mg/kg. PF-2545920 also exhibits antipsychotic-like properties by increasing prepulse inhibition (PPI) in C57BL/6J mice. PF-2545920 also dose-dependently decreases locomotor activity with 0.3 mg/kg reducing activity. [3] In vivo, PF-2545920 inhibits conditioned avoidance responding (CAR) and antagonizes phencyclidine- and amphetamine-induced hyperactivity in rats with AED50 of 0.7, 1 and 4.4 mg/kg sc, respectively. [4]

Protocols

PF-2545920 is dissolved and administered in a vehicle containing 10% DMSO and 20% (2-hydroxypropyl)-β-cyclodextrine. [1]

References

[1] Celen S, et al. Preclinical evaluation of 18F-JNJ41510417 as a radioligand for PET imaging of phosphodiesterase-10A in the brain. J Nucl Med. 2010, 51(10): 1584-1591.
[2] Tu Z, et al. Radiosynthesis and in vivo evaluation of [11C]MP-10 as a PET probe for imaging PDE10A in rodent and non-human primate brain. Bioorg Med Chem. 2011, 19(5): 1666-1673.
[3] Grauer SM, et al. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther. 2009, 331(2): 574-590.
[4] Izco-Basurko I, et al. Highlights from the 236th American Chemical Society (ACS) National Meeting & Exposition. Drugs Fut. 2008, 33(11): 991.

Please click here to fill online order form, and we will make sure to supply you product with detail information. This process usually takes between 24 to 48 hours, depending on products stock avaliability. All inquires and subsequent projects are handled in the strictest confidence and will be backed by a confidentiality agreement if required.
KareBayTM provides scientists and clinicians with a wide range of biotechnological products and science lab supplies for chemical research and analyzing life processes. KareBay's extensive capabilities include commercializing reagents and kits, manufacturing biotech products and providing contract research services to organizations worldwide. Our many global labs, offices, and business partners enable KareBay to extend its products and services to its customer base around the world.

Our products are used for research, laboratory and further evaluation purposes. They are not for human use.